About Us
NextWave Research was created to address the dearth of professional Wall Street research coverage for quality small-cap companies. We believe that quality companies who choose to sponsor research analyst coverage provide a desperately needed service to both individual and institutional investors with reports and commentary freely available to all.
Stephen M. Dunn
Most Recently, Mr. Dunn was Managing Director of Life Sciences Research at Jesup & Lamont. Previously, Mr. Dunn was Director of Research for Dawson James Securities, a full-service investment firm specializing in the healthcare and biotechnology industry. Mr. Dunn performs Wall Street institutional research on both public and private companies in the biotechnology, pharmaceutical and medical device sectors. Previous to Dawson James, he served as Director of Life Sciences at Cabot Adams for the life sciences venture capital group.
He has also held management positions in Business Development, Finance and Operations having worked in over 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson), Telectronics (St. Jude Medical) as well as several smaller companies. With over 25 years within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, M&A and joint ventures with companies such as GlaxoSmithKline, Pharmacia, Novartis, Bayer, Schering AG, Wyeth, Eli Lilly, Pfizer, Genzyme, Martek Biosciences, Fisher Life Sciences, Becton Dickinson, Idec Pharmaceuticals, Ortho Diagnostics, DakoCytomation, Los Alamos and Sandia National Laboratories, the Mayo Clinic Foundation and the Dana-Farber Institute along with dozens of smaller public and private companies throughout the world.
Mr. Dunn is a 5-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media such as The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is also a frequent speaker and panel member for many financial, medical and venture capital events.
John M. Putnam, CFA
Mr. Putnam has been covering the Medical Device and Technology industry on Wall Street for more than 30 years. He previously served as Senior Medical Device Analyst at Dawson James and Stanford Financial Group. He also held similar positions at Smith Barney, Wellington Management, L.F. Rothschild, Alex Brown & Sons, Adams, Harkness & Hill, and Gruntal. He was also a principle and co-founder of Belmont Harbor Capital, a boutique investment research and merchant bank in Chicago.
As an analyst for the past three decades, Mr. Putnam has been responsible for the technology, fundamental, regulatory and reimbursement research of the medical device industry. He has extensive knowledge of many segments of the medical device and technology industry including cardiovascular, orthopedics, diagnostics, and urology and the healthcare information industry. He was one of the first analysts on Wall Street to identify angioplasty and Women’s Health as major investment opportunities. He has a strong financial background and actually enjoys reading and analyzing financial statements and performing due diligence. He also spent several years in Washington D.C., focusing on regulatory and reimbursement issues impacting the medical device industry.
In addition to strong writing and personal communications skill, Mr. Putnam also developed a proprietary research methodology that evaluates the competitive position of companies participating in a particular industry segment by analyzing their intellectual property as embodied in a company’s patent portfolio. This methodology can be used to perform strategic planning and business development. It identifies each company’s relative competitive position within a technology and can identify those companies that are either active or have become inactive in research and development in that specific technology. From a business development perspective it can also identify a patent portfolio that may no longer be relevant to its holder but that may be an opportunity for another company.
Mr. Putnam holds an MBA from The George Washington University and a BA from Baldwin-Wallace College. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society.